Loading...
Loading...
Zalicus Inc.
ZLCS a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases and Hydra Biosciences, Inc., a leader in the
discovery and development of novel ion channels, today announced that they
have entered into a collaboration to advance development of Zalicus'
preclinical ion channel modulator product candidates for the treatment of
pain.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in